Journal
NATURE REVIEWS CANCER
Volume 9, Issue 8, Pages 550-562Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc2664
Keywords
-
Categories
Funding
- National Institutes of Health
Ask authors/readers for more resources
There are ample genetic and laboratory studies that suggest the PI3K-Akt pathway is vital to the growth and survival of cancer cells. Inhibitors targeting this pathway are entering the clinic at a rapid pace. In this Review, the therapeutic potential of drugs targeting PI3K-Akt signalling for the treatment of cancer is discussed. I focus on the advantages and drawbacks of different treatment strategies for targeting this pathway, the cancers that might respond best to these therapies and the challenges and limitations that confront their clinical development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available